A phase 3 clinical trial has found that finerenone, a nonsteroidal mineralocorticoid receptor antagonist, produces a significantly greater reduction in a key marker of kidney damage compared to placebo in adults with Type 1 diabetes and chronic kidney disease (CKD). The results were published on March 5, 2026 in the New England Journal of Medicine.
MSc in Chemistry / Life Sciences / Materials Science / related areas. Hostel accommodation will be provided, subject to availability, and will be governed by the rules and regulations of the Institute prevailing at the time of joining of the candidate.
Providing input into final analyses and interpretation including the development of the Clinical Study Reports, publications, and internal / external presentations.
FOLLOW SOPS, GMP, AND ASEPTIC CONDITIONS. PERFORM EQUIPMENT CLEANING AND OPERATION UNDER SUPERVISION.
ASSIST IN BATCH MANUFACTURING ACTIVITIES AS PER BMR.